Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer-Reference-Cited by-同舟云学术

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Published:2019-12-19 Issue:25 Volume:381 Page:2416-2428
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Ray-Coquard Isabelle¹,Pautier Patricia¹,Pignata Sandro¹,Pérol David¹,González-Martín Antonio¹,Berger Regina¹,Fujiwara Keiichi¹,Vergote Ignace¹,Colombo Nicoletta¹,Mäenpää Johanna¹,Selle Frédéric¹,Sehouli Jalid¹,Lorusso Domenica¹,Guerra Alía Eva M.¹,Reinthaller Alexander¹,Nagao Shoji¹,Lefeuvre-Plesse Claudia¹,Canzler Ulrich¹,Scambia Giovanni¹,Lortholary Alain¹,Marmé Frederik¹,Combe Pierre¹,de Gregorio Nikolaus¹,Rodrigues Manuel¹,Buderath Paul¹,Dubot Coraline¹,Burges Alexander¹,You Benoît¹,Pujade-Lauraine Eric¹,Harter Philipp¹

Affiliation:

1. From Centre Léon Bérard (I.R.-C., D.P.), Health Services and Performance Research Lab (EA 7425 HESPER), University Claude Bernard Lyon 1 (I.R.-C.), and Centre Hospitalier Lyon-Sud (B.Y.), Lyon, Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) (I.R.-C., P.P., F.S., C.L.-P., A.L., P.C., M.R., C.D., B.Y., E.P.-L.), Groupe Hospitalier Diaconesses Croix Saint-Simon (F.S.), Hôpital Européen Georges Pompidou (P.C.), Institut Curie, Hôpital Claudius Régaud (M.R.), and Association de...

Funder

AstraZeneca

Merck

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1911361

Cited by 1145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer;Gynecologic Oncology;2024-05

3. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.;Gynecologic Oncology;2024-03

4. The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients;Cancers;2024-02-02

5. Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI];Current Women s Health Reviews;2024-02